The two recent successful fundraisings in 2026 are truly transformational for Circio, and a testament to the major scientific and business development achievements over the past year. We can now substantially scale up our R&D activities with financial visibility well into 2030. We already have an exciting pipeline of upcoming R&D milestones, which can now be accelerated with the aim of validating the circVec platform in new areas and creating novel business opportunities
Circio aims to be the leader in deploying circular RNA to enhance gene therapy for genetic disease